Comment traiter l'hypercalcémie tumorale ? : Urgences cancérologiques = How to treat tumor-induced hypercalcemie : Oncological emergenciesBODY, Jean-Jacques.La Revue du praticien (Paris). 2003, Vol 53, Num 19, pp 2128-2135, issn 0035-2640, 8 p.Article

Psychosocial rehabilitation of cancer patients after curative therapyRONSON, Alain; BODY, Jean-Jacques.Supportive care in cancer. 2002, Vol 10, Num 4, pp 281-291, issn 0941-4355Article

New treatment concepts in breast cancerBASELGA, José; BODY, Jean-Jacques.Seminars in oncology. 2004, Vol 31, Num 5, issn 0093-7754, 93 p., SUP10Serial Issue

Ibandronate reduces skeletal morbidity in patients with breast cancer : IbandronateTRIPATHY, Debu; DIEL, Ingo; BODY, Jean-Jacques et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 64-66, issn 0093-7754, 3 p., SUP10Article

Review of ibandronate in the treatment of Metastatic bone disease: Experience from Phase III trialsTRIPATHY, Debu; BODY, Jean-Jacques; BERGSTRÖM, Bengt et al.Clinical therapeutics. 2004, Vol 26, Num 12, pp 1947-1959, issn 0149-2918, 13 p.Article

Patient management issues in metastatic bone disease : IbandronateCAMERON, David.Seminars in oncology. 2004, Vol 31, Num 5, pp 79-82, issn 0093-7754, 4 p., SUP10Article

Effectiveness and cost of bisphosphonate therapy in tumor bone diseaseBODY, Jean-Jacques.Cancer. 2003, Vol 97, Num 3, pp 859-865, issn 0008-543X, 7 p., SUPConference Paper

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: A pilot studyMANCINI, Isabelle; DUMON, Jean-Claude; BODY, Jean-Jacques et al.Journal of clinical oncology. 2004, Vol 22, Num 17, pp 3587-3592, issn 0732-183X, 6 p.Article

Fibroblast growth factor 23 and its role in phosphate homeostasisRAMON, Isolde; KLEYNEN, Pierre; BODY, Jean-Jacques et al.European journal of endocrinology. 2010, Vol 162, Num 1, pp 1-10, issn 0804-4643, 10 p.Article

Zoledronic acid. Author's ReplyCHEER, Susan M; NOBLE, Stuart; BODY, Jean-Jacques et al.Drugs (Basel). 2001, Vol 61, Num 6, pp 799-806, issn 0012-6667Article

Perspectives on the future of bisphosphonate use in breast cancer patients : IbandronateCLEMONS, Mark; REA, Daniel.Seminars in oncology. 2004, Vol 31, Num 5, pp 87-91, issn 0093-7754, 5 p., SUP10Article

Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancerFUMOLEAU, Pierre; CAMERON, David.Seminars in oncology. 2004, Vol 31, Num 5, pp 45-50, issn 0093-7754, 6 p., SUP10Article

Optimizing treatment for patients with breast cancerCAMERON, David; BELL, Richard.Seminars in oncology. 2004, Vol 31, Num 5, pp 4-5, issn 0093-7754, 2 p., SUP10Article

Optimizing treatment of HER2-positive metastatic breast cancerJONES, Alison L; LEYLAND-JONES, Brian.Seminars in oncology. 2004, Vol 31, Num 5, pp 29-34, issn 0093-7754, 6 p., SUP10Article

Managing metastatic bone disease: Three case studies : IbandronateCOLEMAN, Robert; HEIDENREICH, Axel; BELL, Richard et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 83-86, issn 0093-7754, 4 p., SUP10Article

Bisphosphonates in the treatment of metastatic breast cancerBODY, Jean-Jacques.Journal of mammary gland biology and neoplasia. 2001, Vol 6, Num 4, pp 477-485, issn 1083-3021Article

Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinomaJOURNE, Fabrice; BODY, Jean-Jacques; LECLERCQ, Guy et al.Breast cancer research and treatment. 2004, Vol 86, Num 1, pp 39-53, issn 0167-6806, 15 p.Article

Dosing regimens and main adverse events of bisphosphonatesBODY, Jean-Jacques.Seminars in oncology. 2001, Vol 28, Num 4, pp 49-53, issn 0093-7754, SUP11Conference Paper

Improving patient care through molecular diagnosticsPEREZ, Edith A; PUSZTAI, Lajos; VAN DE VIJVER, Marc et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 14-20, issn 0093-7754, 7 p., SUP10Article

Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)LEONARD, Robert; MILES, David; REICHARDT, Peter et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 21-28, issn 0093-7754, 8 p., SUP10Article

Breast cancer cells release factors that induce apoptosis in human bone marrow stromal cellsFROMIGUE, Olivia; KHEDDOUMI, Naïma; LOMRI, Abderrahim et al.Journal of bone and mineral research (Print). 2001, Vol 16, Num 9, pp 1600-1610, issn 0884-0431Article

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudySTOPECK, Alison T; LIPTON, Allan; FAN, Michelle et al.Journal of clinical oncology. 2010, Vol 28, Num 35, pp 5132-5139, issn 0732-183X, 8 p.Article

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesLIPTON, Allan; STEGER, Guenther G; COLEMAN, Robert et al.Journal of clinical oncology. 2007, Vol 25, Num 28, pp 4431-4437, issn 0732-183X, 7 p.Article

Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone ClubBOONEN, Steven; BODY, Jean-Jacques; BOUTSEN, Yves et al.Osteoporosis international. 2005, Vol 16, Num 3, pp 239-254, issn 0937-941X, 16 p.Article

Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activationJOURNE, Fabrice; LAURENT, Guy; CHABOTEAUX, Carole et al.Breast cancer research and treatment. 2008, Vol 107, Num 1, pp 49-61, issn 0167-6806, 13 p.Article